Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related